Drugmakers Johnson & Johnson, Endo International, AbbVie’s Allergan unit, and Teva Pharmaceutical headed to court on April 19 in California over claims the companies engaged in deceptive marketing practices that fueled the opioid crisis in America.

Just more than half of U.S. adults have received at least one Covid-19 vaccine dose, data from the U.S. Centers for Disease Control and Prevention showed on April 18, with nearly 130 million people aged 18 years or more having received their first shot.

The United States had administered 205,871,913 doses of Covid-19 vaccines in the country as of the morning of April 17 and distributed 264,499,715 doses, the U.S. Centers for Disease Control and Prevention said.

Four drugmakers, including Johnson & Johnson and Teva Pharmaceutical Industries Ltd., will go to trial on April 19 over claims they helped fuel an opioid crisis that has resulted in nearly 500,000 overdose deaths in the United States.

A U.S. panel will meet again next week to discuss whether the pause on the use of Johnson & Johnson’s Covid-19 vaccine should continue, after delaying a vote on the matter earlier this week.

The Biden administration on April 16 said it will invest $1.7 billion to help states and the U.S. Centers for Disease Control and Prevention fight Covid-19 variants that are rapidly spreading across the United States.

Eli Lilly requested cancellation of the U.S. authorization granted to the company’s Covid-19 antibody bamlanivimab, which will now be used in combination with another to achieve greater efficacy against emerging virus variants.

The United States is preparing for the possibility that a booster shot will be needed between nine to 12 months after people are initially vaccinated against Covid-19, a White House official said on April 15.

GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.

Merck is discontinuing development of MK-7710 (formerly known as CD24Fc), a Phase III Covid-19 therapeutic asset acquired from OncoImmune during November 2020.